PEGylated Proteins Market - By Product Type, By Protein Type, By Application, By End Use - Global Forecast, 2025 - 2034

PEGylated Proteins Market Size

The global PEGylated proteins market size was valued at USD 1.8 billion in 2024. The market is expected to grow from USD 2 billion in 2025 to USD 5.1 billion in 2034, at a CAGR of 10.9%. The growth in biologic medicines and biosimilars, such as monoclonal antibodies and recombinant proteins, is boosting the demand for PEGylation technology. The technology stabilizes drugs, prolongs their half-life, and improves their efficacy.
 

For instance, Biopharma PEG states that as of April 2025 the U.S. FDA has approved 42 PEGylated drugs, signifying an increasing acceptance of this technology and contributing to market expansion. Moreover, the increasing prevalence of chronic disorders such as cancer, rheumatoid arthritis, and multiple sclerosis together has increased the requirement for biopharmaceutical products.
 

For example, the World Health Organization (WHO) has stated that over 35 million new cancer cases are expected to be diagnosed in 2050, which is a 77% increase compared to the 20 million mark estimated for 2022. PEGylation enhances the pharmacokinetics and stability of protein therapeutic drugs, allowing for sustained therapeutic action. The market will grow as more investments are made by biopharmaceutical companies in PEGylated proteins to meet the increasing therapeutic demand of these long-term diseases.
 

In addition, the U.S. FDA and European Medicines Agency (EMA) are providing rapid approvals for PEGylated products based on the improved pharmacokinetic properties of these products. For instance, in September 2022, the U.S. FDA had approved eflapegrastim-xnst (ROLVEDON) for the reduction of the risk of infection in adult patients with nonmyeloid malignancies undergoing myelosuppressive treatment. This regulatory approval encouraged pharmaceutical organizations to implement PEGylation technology, thus boosting market expansion and use in other therapeutic segments, ultimately being beneficial to patients through enhanced therapeutic opportunities.
 

PEGylated Proteins Market Trends

• The market is shifting from conventional linear PEGylation to site-specific PEGylation, branched PEGs, and releasable PEG-linkers. These developments improve drug targeting, reduce immunogenicity, and enable controlled release. Enzymatic PEGylation technology is becoming a technique for targeted molecular modification.
   
• Additionally, PEGylation is important in stabilizing lipid nanoparticles (LNPs) and enhancing delivery efficiency for mRNA vaccines and gene therapies. The COVID-19 mRNA vaccines developed by Pfizer-BioNTech and Moderna, which include PEGylated lipids, have encouraged this trend.
   
• Moreover, the patent expirations on biologics have led the biosimilar manufacturers to use PEGylation while creating biobetters that are improved versions of the current biologics with longer half-life and fewer adverse effects. The trend is well seen in oncology uses, like PEGylated granulocyte colony-stimulating factors.
   
• Furthermore, Pharmaceutical and biotech firms are ramping up their research and development spending on PEGylated proteins in partnerships with technology suppliers and CDMOs. For instance, in July 2024, Aligos Therapeutics formed an agreement with Xiamen Amoytop Biotech for Phase1b clinical trials assessing the safety and effectiveness of ALG-000184 in combination with PEGBING (Mipeginterferon alfa-2b), a PEGylated interferon alfa-2b. These collaborations increase PEGylation effectiveness and expand therapeutic uses.
   
• The market has seen growing competition from PEGylated biosimilars, which is decreasing prices and prompting firms to create new PEGylation technologies in order to keep up with the market. Additionally, regulatory bodies are tightening regulations on PEGylated proteins to guarantee their effectiveness and reduce side effects, especially to address long-term safety and immunogenicity issues.
   

PEGylated Proteins Market Analysis

Based on product type, the market is bifurcated into consumables and services. The consumables segment is expected to drive business growth and expand at a CAGR of 10.9%, reaching over USD 3.4 billion by 2034.
 

• Specific PEG derivatives are often required for PEGylated biologics like monoclonal antibodies, enzymes, and cytokines. Distinct PEG reagents are needed for each new drug candidate. As the use of PEGylation in biologics and biosimilars is growing (to improve therapeutic efficacy), the demand for specialized PEG consumables is also increasing.
   
• Additionally, the rising incidence of chronic diseases such as cancer, diabetes, and autoimmune diseases has necessitated better protein-based therapeutics. According to the WHO, the people with diabetes grew from 200 million in 1990 to 830 million in 2022 globally. PEGylated proteins show better pharmacokinetics and reduced immunogenicity, as a result, the adoption of PEGylated drugs for treating chronic disease is increasing, which is contributing to an increasing demand for consumables.
   
• Further, advancements in PEGylation methodologies have allowed for stable and non-immunogenic drugs to be developed. Such advancements have increased the therapeutic potential of protein-based medicines, which has accelerated the need for research and developments in PEGylation consumables.

Based on protein type, the market is segmented into colony stimulating factors, interferons, erythropoietin, recombinant factor VIII, antibodies, and other protein types. The colony stimulating factors (CSF) segment is expected to drive business growth and expand at a CAGR of 11%, reaching over USD 1.8 billion by 2034.
 

• The increasing incidence of hematological disorders, such as leukemia and anemia, has raised the need for colony-stimulating factors. For example, the World Health Organization (WHO) states that in the year 2020, there were approximately 474,519 newly reported cases of leukemia across the globe which made up roughly 2.5% of the total cancer cases. CSF plays a significant role in the management of the increasing burden of hematologic disorders because it compensates for the disease-induced deficiencies and improves the patient’s outcomes.
   
• Additionally, colony-stimulating factors have expanded their role beyond chemotherapy-induced neutropenia. Now they are used for hematopoietic stem cell mobilization and for treating severe chronic neutropenia. Such growth in therapeutic usage has increased the number of patients and has contributed to growth in the segment.
   

Based on application, the market is segmented into cancer treatment, autoimmune diseases, hematological disorders, hepatitis, chronic kidney diseases, gastrointestinal disorders, and other applications. The cancer treatment segment generated a revenue of USD 654.3 million in 2024.
 

• According to the National Cancer Institute (NCI), nearly 20 million new cancer cases and 9.7 million cancer deaths were reported in the year 2022 across the globe. Such a drastic increase in the occurrence of cancer has generated more demand for newer and better treatment protocols. Targeted therapy solutions of PEGylated proteins address the need for efficient cancer therapy, making them indispensable in current oncology.
   
• Additionally, PEGylation of proteins increases protein-based therapeutics through their stability and solubility. This process prolongs the life of the medication in the body and minimizes immune response reactions. These enhancements create more effective cancer treatments with fewer side effects, thereby increasing patient compliance and treatment efficacy.
   

Based on end use, the market is segmented into pharmaceutical and biotechnology companies, CROs and CMOs, and academic and research institutes. The pharmaceutical and biotechnology companies segment generated a revenue of USD 953.6 million in 2024.
 

• Pharma and biotech firms are increasing their research and development spending on PEGylated protein-based drugs. Such spending is aimed at creating targeted medicines with improved efficacy and safety profiles, which would help companies build their therapeutic portfolios.
   
• Moreover, regulatory authority approval of PEGylated protein drugs has expanded treatment opportunities available and stimulated market growth. Government initiatives favoring biopharmaceutical research and development and funding have stimulated enterprises to invest in PEGylation technology, expanding the market.
   
• For instance, in September 2022, the U.S. FDA announced the approval of Stimufend (pegfilgrastim-fpgk), a biosimilar manufactured and marketed by Fresenius Kabi, for non-myeloid malignancy patients.

North America: The U.S. PEGylated proteins market was valued at USD 735.2 million in 2024 and is projected to grow substantially in the coming years.
 

• The U.S. is experiencing a notable increase in the prevalence of chronic conditions like autoimmune disorders and cancer. To illustrate, the U.S. alone has around 200 new cases of multiple sclerosis diagnosed each week, as reported by the Multiple Sclerosis Discovery Forum. Such trends have raised the need for effective treatment strategies such as PEGylated proteins which offer lower immunogenicity and greater clinical efficacy.
   
• Furthermore, the advanced healthcare system in the U.S. and the presence of major market participants, including Merck Millipore, Abcam, and Biopharma PEG Scientific, sponsors the development and commercialization of advanced PEGylated proteins, thus facilitating the market growth.
   

Europe: UK PEGylated proteins market is projected to grow remarkably in the coming years.
 

• In addition, pharmaceutical and biotech companies are increasing spending on the research and development of PEGylated proteins with collaboration of technology providers and CDMOs. For example, Aligos Therapeutics entered in agreement with Xiamen Amoytop Biotech in July 2024 for Phase1b clinical trials of ALG-000184 with PEGBING (Mipeginterferon alfa-2b), which PEGylated Interferon alfa-2b. These partnerships optimize PEGylation processes and broaden its application in medicine.
   
• The market has been experiencing an influx of competition from PEGylated biosimilars, which are driving down costs and driving companies to produce new PEGylation methods. Further, strict regulatory changes on PEGylated proteins are ensuring product efficacy and reducing side effects, to promote long-term safety and immunogenicity.
   

Japan holds a commendable position in the Asia Pacific PEGylated proteins market.
 

• Japan's high elderly population has contributed to increased cases of age-related diseases, such as cancer and chronic kidney disease. For instance, according to the World Health Organization (WHO), in 2023, the life expectancy in Japan averaged 87.14 years for women and 81.09 years for men, which ranks among the highest in the world. This shift in population has boosted the demand for sophisticated treatments, especially PEGylated proteins, which provide greater therapeutic value.
   
• Moreover, Japanese pharmaceutical companies are establishing strategic collaborations with overseas firms to build and sell PEGylated protein therapies. For example, in September 2022, Asahi Kasei Pharma and Swedish Orphan Biovitrum inked a Japan distribution agreement for pegcetacoplan, a PEGylated peptide, for the treatment of paroxysmal nocturnal hemoglobinuria. Such collaborations enable technology transfer, promote innovation, and expand market access.
   

Saudi Arabia in the Middle East and Africa is expected to witness lucrative growth in the PEGylated proteins market.
 

• Chronic conditions such as cancer, diabetes and kidney diseases in Saudi Arabia have surged over the years and have increased the need for modern therapeutic techniques. In 2021, Saudi Arabia had 17.7% diabetes prevalence rate, and 4.27 million adults affected according to the International Diabetes Federation (IDF). This has created an increased demand in Saudi Arabia for the development of PEGilated proteins offering greater efficacy and lower immunogenicity in these treatments.
   
• Moreover, the allocated Saudi Vision 2030 healthcare spending seeks to shift the central focus from economic growth to improving the public health system. This includes robust funding towards biopharmaceutical research and development which propels the use of innovative treatment methods such as PEGilated proteins.
   

PEGylated Proteins Market Share

The market for PEGylated proteins is extremely fragmented, with many pharmaceutical and biotechnology firms providing PEGylated therapeutic proteins. The major players, including Merck KGaA, Thermo Fisher Scientific, NOF Corporation, and JenKem Technology, occupy around 40% of the market share with their experience in PEGylation technologies and huge production capacities. These major firms are investing extensively in sophisticated PEGylation processes to improve the stability, half-life, and efficacy of the proteins.
 

To address increasing demand, companies are forging strategic collaborations with contract manufacturers and research institutions to incorporate advanced PEGylation technology and increase capacity. Moreover, regulatory backing and more streamlined approval processes for PEGylated biologics are fueling innovation and reducing market entry barriers.
 

Emerging players are targeting new PEGylation chemistries, including site-specific PEGylation, and new-generation PEG reagents to enhance drug performance. This competitive environment encourages ongoing innovation in PEGylated protein supply to enable the development of more effective biologics for the treatment of diseases.
 

PEGylated Proteins Market Companies

Prominent players operating in the PEGylated proteins industry include:

• Abcam
• Aurigene Pharmaceutical Services
• Biomatrik
• Biopharma PEG Scientific
• Celares
• Creative PEGworks
• Enzon Pharmaceuticals
• Iris Biotech
• JenKem Technology
• Laysan Bio
• Merck KGaA
• NOF Corporation
• Profacgen
• Quanta BioDesign
• Thermo Fisher Scientific

• Merck KGaA has a strong presence in the market for PEGylated proteins through its MilliporeSigma subsidiary. The company provides PEGylation reagents, conjugation technologies, and custom PEGylation. Its strong global distribution network and collaborations with academic institutions and industry partners strengthen its market position.
   
• NOF Corporation specializes in the innovation of PEGylation technologies, particularly in manufacturing high-purity, functionalized PEG reagents for conjugating proteins. The company's Sunbright PEG derivatives series addresses the long-acting biologics market through drug stabilization and half-life extension.
   
• JenKem Technology is a leader in PEGylation with custom PEG reagent and contract PEGylation offerings. The firm engineers PEG linkers such as branched, multi-arm, and cleavable forms to improve the performance of therapeutic proteins. JenKem Technologies provides controlled PEGylation for refined drug delivery uses.
   

PEGylated Proteins Industry News:

• In February 2022, Merck KGaA, a leading science and technology company, announced the completion of its acquisition of Exelead, a biopharmaceutical CDMO. The acquisition expanded Merck’s Life Science business by enhancing its end-to-end contract development and manufacturing organization (CDMO) services.
   
• In December 2021, Thermo Fisher Scientific announced the acquisition of PPD, one of the key companies offering clinical research services to the biopharma and biotech industry, for USD 17.4 billion. Through this acquisition, Thermo Fisher Scientific intends to provide expansive world-class services across the clinical development spectrum – from scientific research to safety and efficacy assessment, health outcomes evaluation, clinical trial logistical support, clinical development, and pharmaceutical manufacturing.
   

The PEGylated proteins market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Consumables
• Services

Market, By Protein Type

• Colony stimulating factors
• Interferons
• Erythropoietin
• Recombinant factor VIII
• Antibodies
• Other protein types

Market, By Application

• Cancer treatment
• Autoimmune diseases
• Hematological disorders
• Hepatitis
• Chronic kidney diseases
• Gastrointestinal disorders
• Other applications

Market, By End Use

• Pharmaceutical and biotechnology companies
• CROs and CMOs
• Academic and research institutes

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE